Journal
CELL REPORTS
Volume 31, Issue 8, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2020.107684
Keywords
-
Categories
Funding
- Swedish Cancer Society
- Swedish Childhood Cancer Foundation
- EU-MSCA-COFUND
- CanFaster the Crafoord Foundation [754299]
- Gunnar Nilsson Cancer Foundation
- Medical Faculty of Lund University
- Royal Physiographic Society in Lund
- Swedish Research Council
- BioCARE
- NIH [R01 CA 172447]
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is defined by an accumulation of immature myeloid blasts in the bone marrow. To identify key dependencies of AML stem cells in vivo, here we use a CRISPR-Cas9 screen targeting cell surface genes in a syngeneic MLL-AF9 AML mouse model and show that CXCR4 is a top cell surface regulator of AML cell growth and survival. Deletion of Cxcr4 in AML cells eradicates leukemia cells in vivo without impairing their homing to the bone marrow. In contrast, the CXCR4 ligand CXCL12 is dispensable for leukemia development in recipient mice. Moreover. expression of mutated Cxcr4 variants reveals that CXCR4 signaling is essential for leukemia cells. Notably, loss of CXCR4 signaling in leukemia cells leads to oxidative stress and differentiation in vivo. Taken together, our results identify CXCR4 signaling as essential for AML stem cells by protecting them from differentiation independent of CXCL12 stimulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available